Ionis Pharmaceuticals, Inc.
2855 Gazelle Court
About Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc., located in the North San Diego County city of Carlsbad, was founded in 1989 to create advanced, novel medicines to treat complex and challenging diseases. We are the pioneer in the discovery and development of antisense drugs with more than 1300 patents.
Ionis is a challenging, motivating and rewarding environment designed to foster innovation and scientific excellence. Our founding goals have changed little in over 27 years and our success is a direct result of our outstanding employees. We are interested in bringing together individuals with different skill sets into this creative environment to be part of a productive team. Join us and experience our unique culture while you develop and expand your career.
714 articles with Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, February 27th at 11:30 a.m. Eastern Time to discuss its 2018 financial results and report on pipeline and business progress.
First Patient Enrolled in Pivotal Study of RG6042 (IONIS-HTT Rx) for People with Huntington's Disease
First of 4+ Ionis programs expected to advance to pivotal studies this year
Ionis Pharmaceuticals, Inc. today announced that Management will present a Company overview at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 4:00 p.m. PT in San Francisco, CA.
Ionis Pharmaceuticals, Inc. and its Board of Directors announced today that, effective January 2020, Ionis' founder and CEO, Stanley T. Crooke, M.D., Ph.D., will be transitioning from chief executive officer to executive chairman of Ionis' board of directors.
First-in-class therapies using advanced antisense chemistries highlighted at 2018 American Society of Hematology Annual Meeting
Wholly-owned LICA drug for beta-thalassemia, IONIS-TMPRSS6-L Rx, demonstrates therapeutic potential with positive modulation of important disease-related biomarkers and increase of serum hepcidin in initial clinical study
Ionis Pharmaceuticals, Inc. today announced that management will present a company overview at the Jefferies 2018 London Healthcare Conference.
Phase 2 Results on AKCEA-APO(a)-LRx Presented in Late-Breaking Clinical Trial Presentation at AHA Scientific Sessions
Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced that data from the Phase 2 clinical study of AKCEA-APO(a)-LRx in patients with established cardiovascular disease (CVD) and elevated levels of lipoprotein(a), or Lp(a), were presented in a late-breaking clinical trial presentation at the American Heart Association Scientific Sessions in Chicago November 10, 2018.
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that management will host an Investor Day on Friday, December 7th at 7:30 a.m. Eastern Time at Marriott East Side in New York, NY.
Akcea and Ionis Announce Late-Breaking Presentation of Data From AKCEA-APO(a)-LRx at the American Heart Association Scientific Sessions
Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced that clinical data on AKCEA-APO(a)-LRx in patients with established cardiovascular disease (CVD) and elevated levels of lipoprotein(a), or Lp(a), will be presented at the American Heart Association Scientific Sessions in Chicago November 10-12, 2018.
Ionis Pharmaceuticals, Inc. today announced that management will present a company overview at the following investor conferences
Year-to-date revenues increased more than 15% compared to 2017, driven by increased SPINRAZA revenue
Advances in Ionis' Novel Antisense Technology to be Presented at 2018 Society for Neuroscience Meeting
12 presentations highlighting latest data from Ionis' Neurodegenerative Program.
10/26/2018AstraZeneca is presenting literally dozens of abstracts at this week’s American Society of Nephrology Kidney Week Annual Meeting in San Diego. Not only does it represent ongoing research on already approved drugs, but promising pipeline products.
Webcast scheduled for Tuesday, November 6th at 11:30 a.m. Eastern Time
Response rate approximately doubled compared to previous studies with durvalumab alone in refractory head and neck cancer
Every year, the Breakthrough Prize Foundation awards a collective total of $22 million to nine researchers for achievements in the Life Sciences, Fundamental Physics and Mathematics.
10/11/2018Ionis Pharmaceuticals is on a roll. Days after securing regulatory approval from the FDA for Tegsedi, the company inked a deal worth more than $700 million with pharma giant Roche to develop IONIS-FB-L for the treatment of complement-mediated diseases.
Ionis Enters New Collaboration with Partner to Develop IONIS-FB-L Rx for Complement-Mediated Diseases
Transaction valued at up to $760 million, including $75 million upfront payment, plus royalties up to 20%
The U.S. Food and Drug Administration gave Akcea Therapeutics and its parent company Ionis Pharmaceuticals the green light for Tegsedi, its treatment for polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Akcea Therapeutics, Inc. and Ionis Pharmaceuticals, Inc. announced positive topline results from a Phase 2 clinical study of AKCEA-APO(a)-LRx in patients with established cardiovascular disease (CVD) and elevated levels of lipoprotein(a), or Lp(a).